Therapy of Ischemic Cardiomyopathy with the Immunomodulating Agent Pentoxifylline: Results of a Randomized Study

Circulation

Volumn 109, Issue 6, 2004, Pages 750-755

  Sliwa, Karen ^a,b,c   Woodiwiss, Angela ^b   Kone, Veuvette N ^a   Candy, Geoffrey ^a   Badenhorst, Danelle ^b   Norton, Gavin ^b   Zambakides, Chris ^a   Peters, Ferande ^a   Essop, Rafique ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c NONE   (South Africa)

Author keywords

C reactive protein; Cardiomyopathy; Heart failure; Natriuretic peptides; Pentoxifylline

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; FAS ANTIGEN; IMMUNOMODULATING AGENT; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RADIOISOTOPE VENTRICULOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD95; BLOOD PRESSURE; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PENTOXIFYLLINE; PEPTIDE FRAGMENTS; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 1242314227     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000112568.48837.60     Document Type: Article

References (33)

1. Ross R. Mechanism of disease: atherosclerosis and inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Rauchhaus M, Droehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060-3067.
3. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
4. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
5. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-711.
6. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992:257:387-389.
7. Epstein S. The multiple mechanism by which infection may contribute to atherosclerosis development and course. Circ Res. 2002;90:2-4.
8. Sliwa K, Skudicky D, Candy G, et al. Randomised investigation of effects of pentoxifylline on left ventricular performance in idiopathic dilared cardiomyopathy secondary to idiopathic dilated cardiomyopathy. Lancet. 1998;351:1091-1093.
9. Skudicky D, Bergemann A, Sliwa K, et al. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor and carvedilol: results of a randomized study. Circulation. 2001;103:1083-1090.
10. Sliwa K, Woodiwiss A, Candy G, et al. Pentoxifylline modifies cytokine profiles and improves left ventricular performance in patients with decompensated congestive heart failure. Am J Cardiol. 2002;90:118-122.
11. McDonagh TA, Cunningham ADS, Morrison CE, et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart. 2001;86:21-26.
12. Patterson JA, Naughton J, Pietras RJ, et al. Treadmill exercise in assessment of the functional capacity of patients with cardiac disease. Am J Cardiol. 1972;30:757-762.
13. Reiber JHC. Quantitative analysis of left ventricular function from equilibrium gated blood scintigrams: an overview of computer methods. Eur J Nuclear Med. 1985:10:97-110.
14. Sahn DJ, DeMaria A, Kisslo J, et al. for the Committee on M-mode Standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978:58:1072-1083.
15. Mann DL. Inflammatory mediators and the failing heart: past, present and foreseeable future. Circ Res. 2002;91:988-998.
16. Mazzone A, Cusa C, Mazzucchelli I, et al. Increased production of inflammatory cytokines in patients with silent myocardial ischemia. J Am Coll Cardiol. 2001:38:1895-1901.
17. Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83:376-382.
18. Irwin M, Mak S, Mann DL, et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation. 1999;99:1492-1498.
19. Coletta AP, Clark AL, Banarjee P, et al. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail. 2002;4:559-561.
20. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Circulation. 2003;107:3133-3148.
21. Homeister JW, Lucchesi BR. Complement activation and inhibition in myocardial ischaemia and perfusion injury. Annu Rev Pharmacol Toxicol. 1995;34:17-40.
22. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumour necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988;155:1230-1236.
23. Neuner P, Klosner G, Schauer E, et al. Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumour necrosis factor-α by human peripheral blood mononuclear cells. Immunology, 1994;83:262-267.
24. Belloc F, Jaloustre C, Dumain P, et al. Effect of pentoxifylline on apoptosis of cultured cells. J Cardiovasc Pharmacol. 1995:25(suppl 2):S71-S74.
25. Suresh R, Vig M, Bhatia S, et al. Pentoxifylline functions as an adjunct in vivo to enhance T cell immune response by inhibiting activation-induced death. J Immunol. 2002;169:4262-4272.
26. Kajstura J, Chang W, Reiss K, et al. Apoptosis and necrotic myocyte cell death are independent contributing variables in infarct size in rats. Lab Invest. 1996:74:86-107.
27. Krown KA, Page MT, Nguyen C, et al, Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement in the sphingolipid signaling cascade in cardiac cell death. J Clin Invest, 1996;98:2854-2865.
28. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of c-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168.
29. Barna BP, Thomassen MJ, Clements M, et al. Cytokine induction associated with human C-reactive protein. Fed Am Soc Exp Biol J. 1989;3:284-285.
30. De Lemos JA, McGuire DK, Drazner MH, B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316-322.
31. Lecour S, Smith RM, Woodward B, et al. Identification of a novel role for sphingolipid signalling in TNF-alpha and ischaemic preconditioning mediated cardioprotection. J Mol Cell Cardiol. 2002:34:509-518.
32. Kurrelmeyer KM, Michael LH, Baumgarten G, et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA. 2000:10:5456-5461.
33. Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34:50-97.